ストックスクリーナーアプリを入手
5.65
4.05%
0.22
プレマーケット:
5.60
-0.05
-0.88%
Plus Therapeutics Inc (PSTV) 最新ニュース
Plus Therapeutics appoints Randy Goodman to lead market access By Investing.com - Investing.com Australia
Plus Therapeutics Hires Randy Goodman to Lead Market Access and Value Strategy - citybiz
Plus Therapeutics appoints Randy Goodman to lead market access - Investing.com
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - The Manila Times
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
Why is Plus Therapeutics stock gaining Friday? - MSN
PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally - Stocktwits
Trend Report: What are the analyst revisions for Plus Therapeutics IncIs VRSN stock a good investment in YEARMarket Sentiment Review & Community Verified Watchlist Alerts - baoquankhu1.vn
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why Is Plus Therapeutics Stock Gaining Friday?Plus Therapeutics (NASDAQ:PSTV) - Benzinga
Plus Therapeutics recives Nasdaq delinquency notice - MSN
PSTV Should I Buy - Intellectia AI
Plus Therapeutics names Eric Daniels as chief development officer By Investing.com - Investing.com Australia
Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026 - marketscreener.com
Plus Therapeutics, Inc. Files 8-K Disclosing Executive Employment Agreement and Company Information - Minichart
PSTV: Ascendiant Capital Lowers Price Target to $65 on Plus Ther - GuruFocus
Plus Therapeutics appoints Eric J. Daniels as chief development officer By Investing.com - Investing.com India
Plus Therapeutics Appoints New Chief Development Officer - TipRanks
Plus Therapeutics appoints Eric J. Daniels as chief development officer - Investing.com UK
Plus Therapeutics names Eric J. Daniels as Chief Development Officer - TradingView — Track All Markets
Plus Therapeutics (PSTV) hires Eric J. Daniels as Chief Development Officer with equity package - Stock Titan
Plus Therapeutics names Eric Daniels as chief development officer - Investing.com
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline - Bitget
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - Sahm
Pretax income of Plus Therapeutics, Inc. – MUN:XMP1 - TradingView
Dilution adjustment of Plus Therapeutics, Inc. – MUN:XMP1 - TradingView — Track All Markets
Plus Therapeutics stock gains after FDA orphan drug nod - Investing.com
Plus Therapeutics stock gains after FDA orphan drug nod By Investing.com - Investing.com Australia
FDA grants orphan drug status to Plus Therapeutics’ REYOBIQ By Investing.com - Investing.com Australia
Plus Therapeutics (PSTV) Secures FDA Orphan Drug Designation for Reyobiq - GuruFocus
Plus Therapeutics Receives FDA Orphan Drug Designation for REYOBIQ™ in Pediatric Malignant Gliomas and Ependymoma - Minichart
Plus Therapeutics Gains FDA Orphan Status for REYOBIQ - TipRanks
Plus Therapeutics | 8-K: Current report - Moomoo
Plus Therapeutics granted Orphan Drug Designation for Reyobiq - TipRanks
FDA grants orphan drug status to Plus Therapeutics’ REYOBIQ - Investing.com
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ in Pediatric Malignant Gliomas - Bitget
FDA grants Orphan Drug Designation to REYOBIQ from Plus Therapeutics (PSTV) - Stock Titan
FDA orphan status backs Plus drug for rare childhood brain tumors - Stock Titan
Total debt of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - Sahm
Average basic shares outstanding of Plus Therapeutics, Inc. – FWB:XMP1 - tradingview.com
Equity in earnings of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView — Track All Markets
Gross margin % of Plus Therapeutics, Inc. – FWB:XMP1 - TradingView
EBITDA per share of Plus Therapeutics, Inc. – GETTEX:XMP1 - TradingView — Track All Markets
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):